Search results for "INFECTIONS"

showing 10 items of 2671 documents

Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology.

2010

Objective To determine human papillomavirus (HPV) types among cervical smears using polymerase chain reaction (PCR) and to contribute to the knowledge of human papillomavirus genotype distribution and prevalence of oncogenic types in cervical lesions in Spain. Study Design Consensus PCR and direct sequencing of PCR products (DNA HPV typing) were used in a retrospective study to determinate the type or types of HPV on 974 cytology smears of women with abnormal cytology results. Results Of 974 smears, 79.8% were high-risk (H-R) HPVs, 19.7% low-risk (L-R) HPVs, 4.6% indeterminate-risk (I-R) HPVs, considering both single and multiple infections. Multiple infections were detected in 4.7% of the …

OncologyAdultmedicine.medical_specialtyHistologyGenotypeCost effectivenessPopulationPrevalenceUterine Cervical NeoplasmsAlphapapillomavirusCervical intraepithelial neoplasiaPolymerase Chain ReactionPathology and Forensic MedicineGene FrequencyCytologyInternal medicineGenotypemedicinePrevalenceHumansMass ScreeningeducationMass screeningRetrospective StudiesGynecologyVaginal Smearseducation.field_of_studyHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus Infectionsvirus diseasesGeneral Medicinemedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsSquamous intraepithelial lesionSpainDNA ViralFemalebusinessActa cytologica
researchProduct

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

2011

Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …

OncologyAdultmedicine.medical_specialtyInvasive cervical cancerGenotypeUterine Cervical NeoplasmsHPV vaccinesAdenocarcinomaAlphapapillomavirusInternal medicineGenotypemedicineHumansPapillomavirus VaccinesHuman papillomavirusGenotypingAgedGynecologyCervical cancerHuman papillomavirus 16HPV typesVaccinesHpv typesHuman papillomavirus 18business.industryHPV PositivePapillomavirus Infectionsvirus diseasesObstetrics and GynecologyTime trendsMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOncologySpainCervical cancerFemalebusiness
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).

2014

e20513 Background: E mesylate, a nontaxane microtubule dynamics inhibitor, was approved in the U.S in 2010 for the treatment of MBC who have previously received at least 2 MBC chemo regimens, inclu...

OncologyCancer ResearchSchedulemedicine.medical_specialtyMicrotubule dynamicsMesylatebusiness.industrybacterial infections and mycosesmedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundCombined treatmentOncologychemistryInternal medicinepolycyclic compoundsmedicinebacteriaskin and connective tissue diseasesbusinessneoplasmsmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

2021

Abstract The COVID-19 pandemic affected millions of people globally with lasting effects on society, patients, investigators and health institutions. Clinical trials, our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment, have been affected by the pandemic. The pandemic footprint represents both a risk of compromising development of new therapies and an opportunity to elicit discussion over a portfolio of broader reforms, applicable irrespective of pandemics, in order to improve the design and implementation of clinical trials in oncology. The administrative load should be reduced, without affecting the quality of research and principle…

OncologyCancer ResearchTelemedicinemedicine.medical_specialtyOncologiamedia_common.quotation_subjectMedical Oncology:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Quality of life (healthcare):características del estudio::estudio clínico::ensayo clínico [CARACTERÍSTICAS DE PUBLICACIONES]:Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS]Internal medicinePandemic:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]medicinePandèmia de COVID-19 2020-HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]Pandemicsmedia_commonCOVID-19; Humans; Medical Oncology; Pandemics/prevention & control; SARS-CoV-2; TelemedicineSurrogate endpointSARS-CoV-2COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]World populationTelemedicineClinical trialEditorialOncologyGood clinical practiceBusinessAssaigs clínicsESMO open
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

Expression of cell cycle markers and human papillomavirus infection in oral squamous cell carcinoma: use of fuzzy neural networks.

2005

Our aim was to evaluate in oral squamous cell carcinoma (OSCC) the relationship between some cell cycle markers and HPV infection, conditionally to age, gender and certain habits of patients, and to assess the ability of fuzzy neural networks (FNNs) in building up an adequate predictive model based on logic inference rules. Eighteen cases of OSCC were examined by immunohistochemistry for MIB-1, PCNA and survivin expression; presence of HPV DNA was investigated in exfoliated oral mucosa cells by nested PCR (nPCR, MY09-MY11/GP5-GP6), and HPV genotype was determined by direct DNA sequencing. Data were analyzed by traditional statistics (TS) and FNNs. HPV DNA was found in 9/18 OSCCs (50.0 %) wi…

OncologyMaleCancer ResearchSurvivinmedicine.disease_causeInhibitor of Apoptosis ProteinsRisk FactorsOral mucosaPapillomaviridaeAged 80 and overCell CycleSmokingHPV infectionAge FactorsAnatomical pathologyCell cycleMiddle AgedImmunohistochemistryNeoplasm Proteinsoral squamous cell carcinomamedicine.anatomical_structureCell Transformation NeoplasticOncologyCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmscarcinogenesisMicrotubule-Associated ProteinsAdultmedicine.medical_specialtyBiologySex FactorsFuzzy LogicInternal medicineSurvivinmedicineHumanshuman papillomaviruAgedfuzzy neural networkGene Expression ProfilingPapillomavirus Infectionsmedicine.diseaseProliferating cell nuclear antigenstomatognathic diseasesImmunologyDNA Viralbiology.proteinNeural Networks ComputerCarcinogenesisInternational journal of cancer
researchProduct

Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.

2013

Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). Methods Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. Results HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.…

OncologyMaleCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsFluorescent Antibody TechniqueBiologyAntibodies ViralPolymerase Chain ReactionSerologyInternal medicinemedicineBiomarkers TumorOdds RatioHumansLaryngeal NeoplasmsAgedNeoplasm StagingHuman papillomavirus 16ConfoundingPapillomavirus InfectionsCase-control studyHPV infectionCancervirus diseasesOdds ratioOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationRepressor ProteinsOropharyngeal NeoplasmsOropharyngeal NeoplasmLogistic ModelsOncologyCase-Control StudiesImmunologyHuman papillomavirus 16; Oropharyngeal Neoplasms; Papillomavirus InfectionsDNA ViralEtiologyFemaleJournal of the National Cancer Institute
researchProduct

Exposure to UV radiation and risk of Hodgkin lymphoma: A pooled analysis

2013

Ultraviolet radiation (UVR) exposure has been inversely associated with Hodgkin lymphoma (HL) risk, but only inconsistently, only in a few studies, and without attention to HL heterogeneity. We conducted a pooled analysis of HL risk focusing on type and timing of UVR exposure and on disease subtypes by age, histology, and tumor-cell Epstein-Barr virus (EBV) status. Four case-control studies contributed 1320HLcasesand 6381 controls. We estimated lifetime, adulthood, and childhood UVR exposure and history of sunburn and sunlamp use. We used 2-stage estimation with mixed-effects models and weighted pooled effect estimates by inverse marginal variances. We observed statistically significant inv…

OncologyMaleEpstein-Barr Virus InfectionsDNA RepairSunburnSkin PigmentationComorbidityBiochemistryT-Lymphocytes Regulatoryvisual_art.visual_artistimmune system diseaseshemic and lymphatic diseasesYoung adultSunburnAged 80 and overLymphoid NeoplasiaSunbathingintegumentary systemExposure CategoryInside BLOODConfoundingAge FactorsConfounding Factors EpidemiologicHematologyMiddle AgedHodgkin DiseaseEuropeHodgkin lymphoma (HL)visual_artSunlightFemaleAdultmedicine.medical_specialtyAdolescentUltraviolet RaysImmunologyBiologyWhite PeopleYoung AdultSunbathingInternal medicinemedicineHumansUltraviolet radiation (UVR)tumor-cell Epstein-Barr virus (EBV)AgedfungiCase-control studyModels ImmunologicalDose-Response Relationship RadiationCell BiologyOdds ratiomedicine.diseaseRelative riskCase-Control StudiesImmunologyDNA Damage
researchProduct